Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Planar cell polarity gene Fuz triggers apoptosis in neurodegenerative disease models.

Chen ZS, Li L, Peng S, Chen FM, Zhang Q, An Y, Lin X, Li W, Koon AC, Chan TF, Lau KF, Ngo JCK, Wong WT, Kwan KM, Chan HYE.

EMBO Rep. 2018 Jul 19. pii: e45409. doi: 10.15252/embr.201745409. [Epub ahead of print]

PMID:
30026307
2.

Neuronal adaptor FE65 stimulates Rac1-mediated neurite outgrowth by recruiting and activating ELMO1.

Li W, Tam KMV, Chan WWR, Koon AC, Ngo JCK, Chan HYE, Lau KF.

J Biol Chem. 2018 May 18;293(20):7674-7688. doi: 10.1074/jbc.RA117.000505. Epub 2018 Apr 3.

PMID:
29615491
3.

Identification of influenza polymerase inhibitors targeting C-terminal domain of PA through surface plasmon resonance screening.

Lo CY, Li OT, Tang WP, Hu C, Wang GX, Ngo JC, Wan DC, Poon LL, Shaw PC.

Sci Rep. 2018 Feb 2;8(1):2280. doi: 10.1038/s41598-018-20772-9.

4.

A peptidylic inhibitor for neutralizing expanded CAG RNA-induced nucleolar stress in polyglutamine diseases.

Zhang Q, Chen ZS, An Y, Liu H, Hou Y, Li W, Lau KF, Koon AC, Ngo JCK, Chan HYE.

RNA. 2018 Apr;24(4):486-498. doi: 10.1261/rna.062703.117. Epub 2018 Jan 2.

PMID:
29295891
5.

A brain-targeting lipidated peptide for neutralizing RNA-mediated toxicity in Polyglutamine Diseases.

Zhang Q, Yang M, Sørensen KK, Madsen CS, Boesen JT, An Y, Peng SH, Wei Y, Wang Q, Jensen KJ, Zuo Z, Chan HYE, Ngo JCK.

Sci Rep. 2017 Sep 21;7(1):12077. doi: 10.1038/s41598-017-11695-y.

6.

Identification of influenza polymerase inhibitors targeting polymerase PB2 cap-binding domain through virtual screening.

Liu M, Lo CY, Wang G, Chow HF, Ngo JC, Wan DC, Poon LL, Shaw PC.

Antiviral Res. 2017 Aug;144:186-195. doi: 10.1016/j.antiviral.2017.06.009. Epub 2017 Jun 16.

PMID:
28629986
7.

A Camelid-derived Antibody Fragment Targeting the Active Site of a Serine Protease Balances between Inhibitor and Substrate Behavior.

Kromann-Hansen T, Oldenburg E, Yung KW, Ghassabeh GH, Muyldermans S, Declerck PJ, Huang M, Andreasen PA, Ngo JC.

J Biol Chem. 2016 Jul 15;291(29):15156-68. doi: 10.1074/jbc.M116.732503. Epub 2016 May 23.

8.

Assessing a peptidylic inhibitor-based therapeutic approach that simultaneously suppresses polyglutamine RNA- and protein-mediated toxicities in patient cells and Drosophila.

Zhang Q, Tsoi H, Peng S, Li PP, Lau KF, Rudnicki DD, Ngo JC, Chan HY.

Dis Model Mech. 2016 Mar;9(3):321-34. doi: 10.1242/dmm.022350. Epub 2016 Feb 2.

9.

Phosphorylation of FE65 Ser610 by serum- and glucocorticoid-induced kinase 1 modulates Alzheimer's disease amyloid precursor protein processing.

Chow WN, Ngo JC, Li W, Chen YW, Tam KM, Chan HY, Miller CC, Lau KF.

Biochem J. 2015 Sep 15;470(3):303-17. doi: 10.1042/BJ20141485. Epub 2015 Jul 17.

10.

A novel missense mutation in CCDC88C activates the JNK pathway and causes a dominant form of spinocerebellar ataxia.

Tsoi H, Yu AC, Chen ZS, Ng NK, Chan AY, Yuen LY, Abrigo JM, Tsang SY, Tsui SK, Tong TM, Lo IF, Lam ST, Mok VC, Wong LK, Ngo JC, Lau KF, Chan TF, Chan HY.

J Med Genet. 2014 Sep;51(9):590-5. doi: 10.1136/jmedgenet-2014-102333. Epub 2014 Jul 25.

11.

Primary structural features of SR-like protein acinusS govern the phosphorylation mechanism by SRPK2.

Liang N, Zeng C, Tao KP, Sou WH, Hsia HP, Qu D, Lau SN, Ngo JC.

Biochem J. 2014 Apr 1;459(1):181-91. doi: 10.1042/BJ20131091.

PMID:
24444330
12.

Crystal structures of matriptase in complex with its inhibitor hepatocyte growth factor activator inhibitor-1.

Zhao B, Yuan C, Li R, Qu D, Huang M, Ngo JC.

J Biol Chem. 2013 Apr 19;288(16):11155-64. doi: 10.1074/jbc.M113.454611. Epub 2013 Feb 26.

13.

Structural basis for therapeutic intervention of uPA/uPAR system.

Ngo JC, Jiang L, Lin Z, Yuan C, Chen Z, Zhang X, Yu H, Wang J, Lin L, Huang M.

Curr Drug Targets. 2011 Nov;12(12):1729-43. Review.

PMID:
21707478
14.

Structure of catalytic domain of Matriptase in complex with Sunflower trypsin inhibitor-1.

Yuan C, Chen L, Meehan EJ, Daly N, Craik DJ, Huang M, Ngo JC.

BMC Struct Biol. 2011 Jun 22;11:30. doi: 10.1186/1472-6807-11-30.

15.

Interaction study of two diterpenes, cryptotanshinone and dihydrotanshinone, to human acetylcholinesterase and butyrylcholinesterase by molecular docking and kinetic analysis.

Wong KK, Ngo JC, Liu S, Lin HQ, Hu C, Shaw PC, Wan DC.

Chem Biol Interact. 2010 Sep 6;187(1-3):335-9. doi: 10.1016/j.cbi.2010.03.026. Epub 2010 Mar 27.

PMID:
20350537
16.

Adaptable molecular interactions guide phosphorylation of the SR protein ASF/SF2 by SRPK1.

Hagopian JC, Ma CT, Meade BR, Albuquerque CP, Ngo JC, Ghosh G, Jennings PA, Fu XD, Adams JA.

J Mol Biol. 2008 Oct 17;382(4):894-909. doi: 10.1016/j.jmb.2008.07.055. Epub 2008 Jul 26.

17.

Crystal structure of human factor VIII: implications for the formation of the factor IXa-factor VIIIa complex.

Ngo JC, Huang M, Roth DA, Furie BC, Furie B.

Structure. 2008 Apr;16(4):597-606. doi: 10.1016/j.str.2008.03.001.

18.

A sliding docking interaction is essential for sequential and processive phosphorylation of an SR protein by SRPK1.

Ngo JC, Giang K, Chakrabarti S, Ma CT, Huynh N, Hagopian JC, Dorrestein PC, Fu XD, Adams JA, Ghosh G.

Mol Cell. 2008 Mar 14;29(5):563-76. doi: 10.1016/j.molcel.2007.12.017.

19.

SR protein kinase 1 is resilient to inactivation.

Ngo JC, Gullingsrud J, Giang K, Yeh MJ, Fu XD, Adams JA, McCammon JA, Ghosh G.

Structure. 2007 Jan;15(1):123-33.

20.

Interplay between SRPK and Clk/Sty kinases in phosphorylation of the splicing factor ASF/SF2 is regulated by a docking motif in ASF/SF2.

Ngo JC, Chakrabarti S, Ding JH, Velazquez-Dones A, Nolen B, Aubol BE, Adams JA, Fu XD, Ghosh G.

Mol Cell. 2005 Oct 7;20(1):77-89.

Supplemental Content

Support Center